(IN BRIEF) Basilea Pharmaceutica Ltd has received an additional USD 5.4 million from BARDA to continue development of its novel oral antibiotic ceftibuten-ledaborbactam etzadroxil. The antibiotic is being developed for complicated urinary tract infections, including pyelonephritis, particularly infections caused by … Read the full press release
Posted in Business, Financial, Government, Healthcare, Investment, Pharma & Biotech, Science, Switzerland, Technology
Tagged Additional BARDA Support Brings Basilea Funding for Ceftibuten-Ledaborbactam to USD 30.8 Million, Administration for Strategic Preparedness and Response, Allschwil, anti-infectives, antimicrobial resistance, ASPR, BARDA, BARDA Awards Further Funding to Basilea for Ceftibuten-Ledaborbactam Development, Basilea, Basilea Advances Oral Antibiotic Candidate for Complicated Urinary Tract Infections, Basilea Pharmaceutica, Basilea Pharmaceutica Ltd, beta lactam beta lactamase inhibitor, Biomedical Advanced Research and Development Authority, BL/BLI, boronic acid beta-lactamase inhibitor, BSLN, carbapenemases, ceftibuten, ceftibuten ledaborbactam etzadroxil, ceftibuten-ledaborbactam, cephalosporinases, complicated urinary tract infections, Cresemba®, cUTI, David Veitch, Enterobacterales, ESBL, extended spectrum beta-lactamases, Fast Track Designation, fungal infections, Gram-negative bacteria, investigational drug, KPC, ledaborbactam, ledaborbactam etzadroxil, multidrug resistant bacteria, non-dilutive funding, novel oral antibiotic, oral cephalosporin, OXA-48, pyelonephritis, QIDP designation, Qualified Infectious Disease Product, Severe Bacterial Infections, SIX Swiss Exchange, Switzerland, U.S Department of Health and Human Services, U.S. FDA, USD 172 million contract potential, USD 30.8 million total funding, USD 5.4 million funding, Zevtera®
(IN BRIEF) Researchers at the University of Liverpool and the University of Oxford have developed an experimental targeted therapy designed to kill antibiotic-resistant Neisseria gonorrhoeae, the bacterium that causes gonorrhoea. The approach uses an antibody-drug conjugate made up of an … Read the full press release
Posted in Education, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged ADC, AMR, antibiotic-resistant gonorrhoea, antibody-drug conjugate, antimicrobial payload, antimicrobial peptide, antimicrobial resistance, bacterial biology, bacterial enzyme, bacterial surface activation, Candida auris, cellular pathology, Christoph Tang, doi 10.1073/pnas.2534217123, drug-resistant infections, first-line antibiotics, Gonorrhoea, Hayley Lavender, human cell toxicity, IgA protease, immune evasion, infectious disease research, laboratory testing, microbial pathogenesis, molecular linker, multidrug resistant bacteria, N. gonorrhoeae, Neisseria gonorrhoeae, Novel Antibody-Drug Conjugate Shows Promise Against Multidrug-Resistant Neisseria Gonorrhoeae, PNAS, precision antimicrobial therapy, preclinical research, Research Team Develops Precision Antimicrobial Method for Resistant Gonorrhoea, sexually transmitted infection, STI, Targeted Antimicrobial Platform Uses Bacterial Enzyme to Attack Resistant Gonorrhoea, targeted therapy, University of Liverpool, University of Oxford
(IN BRIEF) Basilea Pharmaceutica has received an additional USD 13.3 million from BARDA to continue development of ceftibuten-ledaborbactam etzadroxil, an investigational oral beta-lactam/beta-lactamase inhibitor antibiotic being developed for complicated urinary tract infections, including pyelonephritis. The latest tranche brings BARDA’s total … Read the full press release
Posted in Business, Economy, Financial, Government, Healthcare, Industrial, Management, Marketing, Pharma & Biotech, Science, Switzerland, Technology, Transportation & Logistics
Tagged Administration for Strategic Preparedness and Response, Allschwil, antibiotic resistance, antimicrobial resistance, ASPR, BARDA, BARDA Funding Supports Basilea’s Efforts to Address Unmet Need in Oral Treatment of Complicated Urinary Tract Infections, Basilea, Basilea Pharmaceutica Ltd, Basilea Receives Additional USD 13.3 Million BARDA Funding to Advance Novel Oral Antibiotic Development, Basilea Secures Additional Non-Dilutive Funding to Prepare Ceftibuten-Ledaborbactam for Phase 3 Development, Basilea Secures Additional USD 13.3 Million BARDA Funding to Advance Development of Novel Oral Antibiotic Ceftibuten-Ledaborbactam, beta-lactam, beta-lactamase inhibitor, Biomedical Advanced Research and Development Authority, BL/BLI combination, carbapenemases, ceftibuten, ceftibuten ledaborbactam etzadroxil, ceftibuten-ledaborbactam, cephalosporinases, complicated urinary tract infections, cUTI, David Veitch, Enterobacterales, ESBL, extended spectrum beta-lactamases, Fast Track Designation, Gram-negative bacteria, infectious diseases, KPC, ledaborbactam etzadroxil, MDR Enterobacterales, multidrug resistant bacteria, non-dilutive funding, novel oral antibiotic, OXA-48, phase 3 programme, pyelonephritis, QIDP designation, Qualified Infectious Disease Product, SIX: BSLN, Switzerland, U.S Department of Health and Human Services, U.S. FDA
Ad hoc announcement pursuant to Art. 53 LR (IN BRIEF) Basilea Pharmaceutica has been awarded USD 6 million by the Biomedical Advanced Research and Development Authority to continue development of its investigational oral antibiotic ceftibuten-ledaborbactam etzadroxil for treating complicated urinary … Read the full press release
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, Pharma & Biotech, Science, Security & Safety, Switzerland
Tagged antibiotic development, antimicrobial resistance, ASPR, BARDA, Basilea Advances Antibiotic Pipeline with BARDA Funding for Oral Beta Lactam Combination Therapy, Basilea Pharmaceutica, Basilea Receives USD 6 Million BARDA Funding to Advance Development of Oral Antibiotic for Drug Resistant Urinary Infections, beta lactam beta lactamase inhibitor, ceftibuten ledaborbactam etzadroxil, complicated urinary tract infections cUTI, Cresemba®, David Veitch, FDA Fast Track designation, multidrug resistant bacteria, pyelonephritis, Qualified Infectious Disease Product QIDP, US Department of Health and Human Services, Zevtera®
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?